Hepion Pharmaceuticals, Inc. (HEPA): auditor change — Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor

Hepion Pharmaceuticals, Inc.

BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.
BDO reports for FY 2021 and 2022 contained going-concern explanatory paragraph due to recurring losses and accumulated deficit.
Material weaknesses in internal control over financial reporting identified in prior annual and quarterly reports.
No disagreements with BDO on accounting principles or audit scope during the past two years.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Hepion Pharmaceuticals, Inc. engaged Grassi Advisors as its auditor.

Action: engagement
Auditor: Grassi Advisors

Exact text from the filing

approved the engagement of Grassi Advisors (“Grassi”) as the Company’s independent registered public accounting firm

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Hepion Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its auditor.

Action: dismissal
Auditor: BDO USA, P.C.

Exact text from the filing

the audit committee of the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the dismissal of BDO USA, P.C. (“BDO”) as the Company’s independent registered public accounting firm

View on SEC.gov

19 auditor changes filed in the last 30 days. Browse all auditor changes →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-000860

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.